Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/15142
Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling
Identifiers
eISSN: 1999-4923
WOS ID: 000489151700020
Scopus EID: 2-s2.0-85073328556
PMID: 31547301
Embase PUI: L2002583069
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordPublication date
2019-09Document type
research articleCitation
Rees VE, Bulitta JB, Oliver A, Nation RL, Landersdorfer CB. Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling. Pharmaceutics. 2019 Sep;11(9):470.Abstract
Hypermutable Pseudomonas aeruginosa strains have a greatly increased mutation rate and are prevalent in chronic respiratory infections. Initially, we systematically evaluated the time-course of total and resistant populations of hypermutable (PAO increment mutS) and non-hypermutable (PAO1) P. aeruginosa strains in 48-h static concentration time-kill studies with two inocula. Both strains were exposed to clinically relevant concentrations of important antibiotics (aztreonam, ceftazidime, imipenem, meropenem, tobramycin, and ciprofloxacin) in monotherapy. The combination of tobramycin and ciprofloxacin was subsequently assessed in 48-h static concentration time-kill studies against PAO1, PAO increment mutS, and two hypermutable clinical P. aeruginosa strains. Mechanism-based mathematical modelling was conducted to describe the time-course of total and resistant bacteria for all four strains exposed to the combination. With all monotherapies, bacterial regrowth and resistant populations were overall more pronounced for PAO increment mutS compared to PAO1. The combination of tobramycin and ciprofloxacin was synergistic, with up to 10(6.1) colony forming units (CFU)/mL more bacterial killing than the most active monotherapy for all strains, and largely suppressed less-susceptible populations. This work indicates that monotherapies against hypermutable P. aeruginosa strains are not a viable option. Tobramycin with ciprofloxacin was identified as a promising and tangible option to combat hypermutable P. aeruginosa strains.
Publisher version
https://dx.doi.org/10.3390/pharmaceutics11090470Keywords
hypermutableantipseudomonals
antibiotic resistance
antibiotic combination
mechanism-based modelling
This item appears in following Docusalut collections
Hospital Universitario Son Espases - HUSE > Comunicación científicaInstituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica